The global poly (ADP-Ribose) polymerase (PARP) inhibitors market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Poly polymerase term is derived from PARP or the poly (adenosine diphosphate [ADP] -ribose) polymerase. It is a family of 17 enzymes that combine several (poly) units of ADP-ribose in a chain (the PAR chain) and transfers them to the target proteins. This supports to restore DNA when it is damaged. DNA can be damaged by many factors, including exposure to UV rays, radiation, some anti-cancer drugs, or other substances in the environment. PARP inhibitors block an enzyme critical to the repair of single stranded breaks in DNA. Inhibition of this DNA repair enzyme can lead to cell death, particularly in cancer cells that carry deficiency in other DNA repair pathways. The major factor attributable to the market growth includes the growing prevalence of cancer all over the globe. For instance, ovarian cancer is the second most common gynecologic cancer in the US. 

The American Cancer Society (ACS) estimates that in 2022, there will be nearly 19,880 women receiving a new diagnosis of ovarian cancer in the US. Combination therapies, specifically those including checkpoint inhibitors, are poised to be introduced in the first-line setting to target major unmet needs including overcoming tumor resistance, improving progression-free survival, and maintaining the quality of life. PARP inhibitors play an effective maintenance role in current cancer-combating strategies with its superior effect to that of existing ovarian cancer treatment. Currently, Talazoparib and Veliparib are in Phase III clinical trials and Rucaparib, Olaparib and Niraparib are approved PARP drugs which are currently present in the market for ovarian cancer treatment. PARP inhibitors improve progression-free survival in women with recurrent ovarian cancer, sensitive to platinum.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Drugs 

o By Indication

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Pfizer Inc., AstraZeneca plc and GlaxoSmithKline plc, among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Report by Segment

By Drugs

• Talazoparib
• Veliparib 
• Olaparib
• Others

By Indication

• Ovarian Cancer 
• Fallopian Tube Cancer 
• Breast Cancer
• Others

Global Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa